4 Matching Annotations
  1. Dec 2024
  2. Jul 2021
    1. (TMPRSS2)

      The inhibitor of TMPRSS2, N-0385, administered intranasally, has recently been shown to improve clinical outcomes in the severe K18-human ACE2 transgenic mouse model of SARS-CoV-2 disease. This is another potential novel therapeutic for patients suffering with COVID-19 (DOI: 10.1101/2021.05.03.442520).